Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Caroline Crombie is active.

Publication


Featured researches published by Caroline Crombie.


Nature | 2009

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

Shaun Purcell; Naomi R. Wray; Jennifer Stone; Peter M. Visscher; Michael Conlon O'Donovan; Patrick F. Sullivan; Pamela Sklar; Douglas M. Ruderfer; Andrew McQuillin; Derek W. Morris; Colm O’Dushlaine; Aiden Corvin; Peter Holmans; Michael C. O’Donovan; Stuart MacGregor; Hugh Gurling; Douglas Blackwood; Nicholas John Craddock; Michael Gill; Christina M. Hultman; George Kirov; Paul Lichtenstein; Walter J. Muir; Michael John Owen; Carlos N. Pato; Edward M. Scolnick; David St Clair; Nigel Melville Williams; Lyudmila Georgieva; Ivan Nikolov

Schizophrenia is a severe mental disorder with a lifetime risk of about 1%, characterized by hallucinations, delusions and cognitive deficits, with heritability estimated at up to 80%. We performed a genome-wide association study of 3,322 European individuals with schizophrenia and 3,587 controls. Here we show, using two analytic approaches, the extent to which common genetic variation underlies the risk of schizophrenia. First, we implicate the major histocompatibility complex. Second, we provide molecular genetic evidence for a substantial polygenic component to the risk of schizophrenia involving thousands of common alleles of very small effect. We show that this component also contributes to the risk of bipolar disorder, but not to several non-psychiatric diseases.


Nature | 2008

Large recurrent microdeletions associated with schizophrenia.

Hreinn Stefansson; Dan Rujescu; Sven Cichon; Olli Pietiläinen; Andres Ingason; Stacy Steinberg; Ragnheidur Fossdal; Engilbert Sigurdsson; T. Sigmundsson; Jacobine E. Buizer-Voskamp; Thomas V O Hansen; Klaus D. Jakobsen; Pierandrea Muglia; Clyde Francks; Paul M. Matthews; Arnaldur Gylfason; Bjarni V. Halldórsson; Daniel F. Gudbjartsson; Thorgeir E. Thorgeirsson; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Aslaug Jonasdottir; Asgeir Björnsson; Sigurborg Mattiasdottir; Thorarinn Blondal; Magnus Haraldsson; Brynja B. Magnusdottir; Ina Giegling; Hans-Jürgen Möller; Annette M. Hartmann

Reduced fecundity, associated with severe mental disorders, places negative selection pressure on risk alleles and may explain, in part, why common variants have not been found that confer risk of disorders such as autism, schizophrenia and mental retardation. Thus, rare variants may account for a larger fraction of the overall genetic risk than previously assumed. In contrast to rare single nucleotide mutations, rare copy number variations (CNVs) can be detected using genome-wide single nucleotide polymorphism arrays. This has led to the identification of CNVs associated with mental retardation and autism. In a genome-wide search for CNVs associating with schizophrenia, we used a population-based sample to identify de novo CNVs by analysing 9,878 transmissions from parents to offspring. The 66 de novo CNVs identified were tested for association in a sample of 1,433 schizophrenia cases and 33,250 controls. Three deletions at 1q21.1, 15q11.2 and 15q13.3 showing nominal association with schizophrenia in the first sample (phase I) were followed up in a second sample of 3,285 cases and 7,951 controls (phase II). All three deletions significantly associate with schizophrenia and related psychoses in the combined sample. The identification of these rare, recurrent risk variants, having occurred independently in multiple founders and being subject to negative selection, is important in itself. CNV analysis may also point the way to the identification of additional and more prevalent risk variants in genes and pathways involved in schizophrenia.


Nature | 2008

Rare chromosomal deletions and duplications increase risk of schizophrenia

Jennifer Stone; Michael C. O’Donovan; Hugh Gurling; George Kirov; Douglas Blackwood; Aiden Corvin; Nicholas John Craddock; Michael Gill; Christina M. Hultman; Paul Lichtenstein; Andrew McQuillin; Carlos N. Pato; Douglas M. Ruderfer; Michael John Owen; David St Clair; Patrick F. Sullivan; Pamela Sklar; Shaun Purcell; Joshua M. Korn; Stuart Macgregor; Derek W. Morris; Colm O’Dushlaine; Mark J. Daly; Peter M. Visscher; Peter Holmans; Edward M. Scolnick; Nigel Melville Williams; Lucy Georgieva; Ivan Nikolov; Nadine Norton

Schizophrenia is a severe mental disorder marked by hallucinations, delusions, cognitive deficits and apathy, with a heritability estimated at 73–90% (ref. 1). Inheritance patterns are complex, and the number and type of genetic variants involved are not understood. Copy number variants (CNVs) have been identified in individual patients with schizophrenia and also in neurodevelopmental disorders, but large-scale genome-wide surveys have not been performed. Here we report a genome-wide survey of rare CNVs in 3,391 patients with schizophrenia and 3,181 ancestrally matched controls, using high-density microarrays. For CNVs that were observed in less than 1% of the sample and were more than 100 kilobases in length, the total burden is increased 1.15-fold in patients with schizophrenia in comparison with controls. This effect was more pronounced for rarer, single-occurrence CNVs and for those that involved genes as opposed to those that did not. As expected, deletions were found within the region critical for velo-cardio-facial syndrome, which includes psychotic symptoms in 30% of patients. Associations with schizophrenia were also found for large deletions on chromosome 15q13.3 and 1q21.1. These associations have not previously been reported, and they remained significant after genome-wide correction. Our results provide strong support for a model of schizophrenia pathogenesis that includes the effects of multiple rare structural variants, both genome-wide and at specific loci.


British Journal of Clinical Psychology | 2001

Normative data for the HADS from a large non-clinical sample.

John R. Crawford; Julie D. Henry; Caroline Crombie; Emily Taylor

OBJECTIVES To provide normative data for the Hospital Anxiety Depression Scale (HADS). DESIGN Repeated measures and correlational. METHODS The HADS was administered to a non-clinical sample, broadly representative of the general adult UK population (N = 1792) in terms of the distributions of age, gender and occupational status. Correlational analysis was used to determine the influence of demographic variables on HADS scores. RESULTS Demographic variables had only very modest influences on HADS scores. The reliability of the HADS is acceptable; the Anxiety and Depression scales are moderately correlated (.53). Tables to convert raw scores to percentiles are presented for females and males. CONCLUSIONS The present normative data allow clinicians to assess the rarity of a given HADS score, and thus provide a useful supplement to existing cut-off scores.


PLOS Genetics | 2009

A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia

Anna C. Need; Dongliang Ge; Michael E. Weale; Jessica M. Maia; Sheng Feng; Erin L. Heinzen; Woohyun Yoon; Dalia Kasperavičiūtė; Massimo Gennarelli; Warren J. Strittmatter; Cristian Bonvicini; Giuseppe Rossi; Karu Jayathilake; Philip A. Cola; Joseph P. McEvoy; Richard S.E. Keefe; Elizabeth M. C. Fisher; Pamela L. St. Jean; Ina Giegling; Annette M. Hartmann; Hans-Jürgen Möller; Andreas Ruppert; Gillian M. Fraser; Caroline Crombie; Lefkos T. Middleton; David St Clair; Allen D. Roses; Pierandrea Muglia; Clyde Francks; Dan Rujescu

We report a genome-wide assessment of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) in schizophrenia. We investigated SNPs using 871 patients and 863 controls, following up the top hits in four independent cohorts comprising 1,460 patients and 12,995 controls, all of European origin. We found no genome-wide significant associations, nor could we provide support for any previously reported candidate gene or genome-wide associations. We went on to examine CNVs using a subset of 1,013 cases and 1,084 controls of European ancestry, and a further set of 60 cases and 64 controls of African ancestry. We found that eight cases and zero controls carried deletions greater than 2 Mb, of which two, at 8p22 and 16p13.11-p12.4, are newly reported here. A further evaluation of 1,378 controls identified no deletions greater than 2 Mb, suggesting a high prior probability of disease involvement when such deletions are observed in cases. We also provide further evidence for some smaller, previously reported, schizophrenia-associated CNVs, such as those in NRXN1 and APBA2. We could not provide strong support for the hypothesis that schizophrenia patients have a significantly greater “load” of large (>100 kb), rare CNVs, nor could we find common CNVs that associate with schizophrenia. Finally, we did not provide support for the suggestion that schizophrenia-associated CNVs may preferentially disrupt genes in neurodevelopmental pathways. Collectively, these analyses provide the first integrated study of SNPs and CNVs in schizophrenia and support the emerging view that rare deleterious variants may be more important in schizophrenia predisposition than common polymorphisms. While our analyses do not suggest that implicated CNVs impinge on particular key pathways, we do support the contribution of specific genomic regions in schizophrenia, presumably due to recurrent mutation. On balance, these data suggest that very few schizophrenia patients share identical genomic causation, potentially complicating efforts to personalize treatment regimens.


Human Molecular Genetics | 2009

Disruption of the neurexin 1 gene is associated with schizophrenia

Dan Rujescu; Andres Ingason; Sven Cichon; Olli Pietiläinen; Michael R. Barnes; Timothea Toulopoulou; Marco Picchioni; Evangelos Vassos; Ulrich Ettinger; Elvira Bramon; Robin M. Murray; Mirella Ruggeri; Sarah Tosato; Chiara Bonetto; Stacy Steinberg; Engilbert Sigurdsson; T. Sigmundsson; Hannes Petursson; Arnaldur Gylfason; Pall Olason; Gudmundur Hardarsson; Gudrun A Jonsdottir; Omar Gustafsson; Ragnheidur Fossdal; Ina Giegling; Hans-Jürgen Möller; Annette M. Hartmann; Per Hoffmann; Caroline Crombie; Gillian M. Fraser

Deletions within the neurexin 1 gene (NRXN1; 2p16.3) are associated with autism and have also been reported in two families with schizophrenia. We examined NRXN1, and the closely related NRXN2 and NRXN3 genes, for copy number variants (CNVs) in 2977 schizophrenia patients and 33 746 controls from seven European populations (Iceland, Finland, Norway, Germany, The Netherlands, Italy and UK) using microarray data. We found 66 deletions and 5 duplications in NRXN1, including a de novo deletion: 12 deletions and 2 duplications occurred in schizophrenia cases (0.47%) compared to 49 and 3 (0.15%) in controls. There was no common breakpoint and the CNVs varied from 18 to 420 kb. No CNVs were found in NRXN2 or NRXN3. We performed a Cochran-Mantel-Haenszel exact test to estimate association between all CNVs and schizophrenia (P = 0.13; OR = 1.73; 95% CI 0.81-3.50). Because the penetrance of NRXN1 CNVs may vary according to the level of functional impact on the gene, we next restricted the association analysis to CNVs that disrupt exons (0.24% of cases and 0.015% of controls). These were significantly associated with a high odds ratio (P = 0.0027; OR 8.97, 95% CI 1.8-51.9). We conclude that NRXN1 deletions affecting exons confer risk of schizophrenia.


Molecular Psychiatry | 2005

BDNF gene is a risk factor for schizophrenia in a Scottish population.

M. Neves-Pereira; John Kwok Shing Cheung; Alireza Pasdar; Feng Zhang; Gerome Breen; P Yates; Maggie Sinclair; Caroline Crombie; Nicholas Walker; D. St Clair

Schizophrenia is a severe psychiatric disease with a strong genetic component. Brain-derived neurotrophic factor (BDNF) has been implicated in the pathogenesis of schizophrenia and bipolar (BP) disorders. The present study has examined two polymorphisms in linkage disequilibrium in the BDNF gene, which have been variously reported as associated with schizophrenia and BP. In our study, 321 probands with a primary diagnosis of schizophrenia or schizoaffective disorder, and 263 with a diagnosis of bipolar affective disorder, were examined together with 350 controls drawn from the same geographical region of Scotland. The val66met single-nucleotide polymorphism (SNP) showed significant (P=0.005) association for valine (allele G) with schizophrenia but not bipolar disorder. Haplotype analysis of val/met SNP and a dinucleotide repeat polymorphism in the putative promoter region revealed highly significant (P<1 × 10−8) under-representation of the methionine or met-1 haplotype in the schizophrenic but not the BP population. We conclude that, although the val66met polymorphism has been reported to alter gene function, the risk may depend upon the haplotypic background on which the val/met variant is carried.


Molecular Psychiatry | 2011

Copy number variations of chromosome 16p13.1 region associated with schizophrenia

Andres Ingason; Dan Rujescu; Sven Cichon; Engilbert Sigurdsson; T. Sigmundsson; Olli Pietiläinen; Jacobine E. Buizer-Voskamp; Eric Strengman; Clyde Francks; Pierandrea Muglia; Arnaldur Gylfason; Omar Gustafsson; Pall Olason; Stacy Steinberg; Thomas V O Hansen; Klaus D. Jakobsen; Henrik B. Rasmussen; Ina Giegling; H.-J. Möller; Annette M. Hartmann; Caroline Crombie; Gillian M. Fraser; Nicholas Walker; Jan-Erik Lönnqvist; Jaana Suvisaari; Annamari Tuulio-Henriksson; Elvira Bramon; Lambertus A. Kiemeney; Barbara Franke; Robin M. Murray

Deletions and reciprocal duplications of the chromosome 16p13.1 region have recently been reported in several cases of autism and mental retardation (MR). As genomic copy number variants found in these two disorders may also associate with schizophrenia, we examined 4345 schizophrenia patients and 35 079 controls from 8 European populations for duplications and deletions at the 16p13.1 locus, using microarray data. We found a threefold excess of duplications and deletions in schizophrenia cases compared with controls, with duplications present in 0.30% of cases versus 0.09% of controls (P=0.007) and deletions in 0.12 % of cases and 0.04% of controls (P>0.05). The region can be divided into three intervals defined by flanking low copy repeats. Duplications spanning intervals I and II showed the most significant (P=0.00010) association with schizophrenia. The age of onset in duplication and deletion carriers among cases ranged from 12 to 35 years, and the majority were males with a family history of psychiatric disorders. In a single Icelandic family, a duplication spanning intervals I and II was present in two cases of schizophrenia, and individual cases of alcoholism, attention deficit hyperactivity disorder and dyslexia. Candidate genes in the region include NTAN1 and NDE1. We conclude that duplications and perhaps also deletions of chromosome 16p13.1, previously reported to be associated with autism and MR, also confer risk of schizophrenia.


American Journal of Medical Genetics | 2006

Genetic association between schizophrenia and the DISC1 gene in the Scottish population

Feng Zhang; Jane Sarginson; Caroline Crombie; Nick Walker; David StClair; Duncan Shaw

Several lines of evidence support the involvement of the disrupted in schizophrenia 1 (DISC1) gene in schizophrenia susceptibility, including its original identification in a schizophrenia family with a chromosome translocation, several genetic association studies, and functional characterization of the gene product. In the present study, we have genotyped multiple SNP and microsatellite markers in a large Scottish case‐control sample. We identified two SNPs and one microsatellite that show significant association with schizophrenia. The strongest association is with a haplotype of SNPs rs751229 and rs3738401, located at the 5′ end of the gene; the C‐A haplotype of these SNPs is associated with a relative risk of schizophrenia of 5 in our population. We also observe association with a microsatellite in intron 7, but no association with markers toward the 3′ end of the gene. The results are in broad agreement with those of other genetic studies, but there are differences in terms of the precise patterns of association. This analysis further strengthens the candidacy of DISC1 as a risk factor for schizophrenia in the general population, and suggests that more intensive searching for causative variants is justified.


Molecular Psychiatry | 2005

Identifying potential risk haplotypes for schizophrenia at the DTNBP1 locus in Han Chinese and Scottish populations

Tao Li; Fuchang Zhang; X Liu; Xueli Sun; Pak Sham; Caroline Crombie; Xiaohong Ma; Qingzhong Wang; Huaqing Meng; Wei Deng; P Yates; Xun Hu; Nicholas Walker; Robin M. Murray; D. St Clair; David A. Collier

The dystrobrevin-binding protein 1 (DTNBP1) gene on chromosome 6p has emerged as a potential susceptibility gene for schizophrenia. Although a number of attempts to replicate the original association finding have been successful, they have not identified any obvious pathogenic variants or a single at risk haplotype common to all populations studied. In the present study we attempted further replication in an independent sample of 638 nuclear families from the Han Chinese population of Sichuan Province, SW China. We also examined 580 Scottish schizophrenic cases and 620 controls. We genotyped 10 single-nucleotide polymorphisms (SNPs) in DTNBP1 that were used in the original report of association, plus rs2619538 (SNP ‘A’) in the putative promoter region, which has also been associated with schizophrenia. In the Chinese trios we found that two SNPs (P1635 and P1765) were significantly overtransmitted, but with alleles opposite to those reported in the original studies. SNPs P1757 and P1765 formed a common haplotype, which also showed significant overtransmission. In the Scottish cases and controls, no individual markers were significantly associated with schizophrenia. A single haplotype, which included rs2619538 and P1583, and one rare haplotype, composed of P1320 and P1757, were significantly associated with schizophrenia, but no previously reported haplotypes were associated. Based on the data from the Chinese population, our results provide statistical support for DTNBP1 as a susceptibility gene for schizophrenia, albeit with haplotypes different from those of the original study. However, our lack of replication in the Scottish samples also indicates that caution is warranted when evaluating the robustness of the evidence for DTNBP1 as genetic risk factor for schizophrenia.

Collaboration


Dive into the Caroline Crombie's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. St Clair

University of Aberdeen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

P Yates

University of Aberdeen

View shared research outputs
Top Co-Authors

Avatar

Hugh Gurling

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge